Given that Hispanic patients often develop adenomas and CRC at a younger age, have a greater incidence of MLH1 and PMS2 variants, and are less likely to receive appropriate screening, these patients represent a vulnerable population that may require further analysis for evidence-based screening and management guidelines (14). The gene discussed is PMS2; the disease is adenoma.